The medicalization of psychedelics is an ongoing debate. Proponents highlight potential mental health breakthroughs, while opponents cite safety risks and advocate for continued prohibition.
Clinical-only access also helps standardize dosing, screening, and integration therapy. Without that, hype could outpace actual patient support.
